These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23456679)

  • 1. The FDA, bridging data, and hepatitis C.
    Fried MW; Jensen DM
    Hepatology; 2013 Mar; 57(3):875-7. PubMed ID: 23456679
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA bridging analyses confirmed in clinical trial.
    Mishra P; Florian J; Murray J
    Hepatology; 2014 Dec; 60(6):2134. PubMed ID: 24591059
    [No Abstract]   [Full Text] [Related]  

  • 3. Boceprevir dosing for late responders and null responders: the role of bridging data between treatment-naïve and -experienced subjects.
    Florian J; Jadhav PR; Amur S; Ayala R; Harrington P; Mishra P; O'Rear J; Pacanowski M; Robertson S; Singer M; Soon G; Zeng W; Murray J
    Hepatology; 2013 Mar; 57(3):903-7. PubMed ID: 22610696
    [No Abstract]   [Full Text] [Related]  

  • 4. Telaprevir and boceprevir: a potential role for therapeutic drug monitoring.
    Dolton MJ; Ray JE; McLachlan AJ
    Ther Drug Monit; 2013 Jun; 35(3):414-5. PubMed ID: 23670484
    [No Abstract]   [Full Text] [Related]  

  • 5. A major advance in treating hepatitis C.
    Johns Hopkins Med Lett Health After 50; 2011 Dec; 23(10):6. PubMed ID: 22216468
    [No Abstract]   [Full Text] [Related]  

  • 6. Infectious diseases. First specific drugs raise hopes for hepatitis C.
    Enserink M
    Science; 2011 Apr; 332(6026):159-60. PubMed ID: 21474720
    [No Abstract]   [Full Text] [Related]  

  • 7. [Hepatitis C update: what has changed? What can we expect in the near future?].
    Geier A
    MMW Fortschr Med; 2013 Nov; 155(19):59-62. PubMed ID: 24475674
    [No Abstract]   [Full Text] [Related]  

  • 8. Triple therapy for hepatitis C.
    Giordano C
    JAAPA; 2012 Feb; 25(2):59-60. PubMed ID: 22416558
    [No Abstract]   [Full Text] [Related]  

  • 9. Hepatitis C virus treatment: the unyielding chasm between efficacy and effectiveness.
    Kanwal F; El-Serag HB
    Clin Gastroenterol Hepatol; 2014 Aug; 12(8):1381-3. PubMed ID: 24607698
    [No Abstract]   [Full Text] [Related]  

  • 10. Two drugs approved for chronic hepatitis C infection.
    Traynor K
    Am J Health Syst Pharm; 2011 Jul; 68(13):1176. PubMed ID: 21690418
    [No Abstract]   [Full Text] [Related]  

  • 11. [A new era in therapy of hepatitis C: "the therapy can now be individualized" (interview by Dr. med. Dirk Einecke)].
    Manns M
    MMW Fortschr Med; 2011 Jul; 153(29-31):17. PubMed ID: 21830729
    [No Abstract]   [Full Text] [Related]  

  • 12. [Successful eradication of genotype 4 HCV with telaprevir-based triple antiviral therapy].
    Deneke MG; Dranoff JA; Duarte-Rojo A
    Rev Gastroenterol Mex; 2014; 79(1):64-6. PubMed ID: 24679642
    [No Abstract]   [Full Text] [Related]  

  • 13. Update on the use of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection.
    Fernández-Yunquera A; Rincón D; Salcedo M; Bañares R
    Rev Esp Quimioter; 2013 Sep; 26(3):189-92. PubMed ID: 24080883
    [No Abstract]   [Full Text] [Related]  

  • 14. Effectiveness research in the evolving HCV landscape.
    Backus LI; Belperio PS
    Dig Dis Sci; 2014 Dec; 59(12):2845-7. PubMed ID: 25190262
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapy of hepatitis C: new inhibitors as hammers against HCV].
    Bublak R
    MMW Fortschr Med; 2013 Jun; 155 Suppl 1():10-1. PubMed ID: 23961643
    [No Abstract]   [Full Text] [Related]  

  • 16. New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye.
    Dusheiko G; Wedemeyer H
    Gut; 2012 Dec; 61(12):1647-52. PubMed ID: 22936671
    [No Abstract]   [Full Text] [Related]  

  • 17. Protease inhibitors in hepatitis C: from chronic disease to cure.
    Iqbal M; McCormick PA
    Ir Med J; 2011 Sep; 104(8):230-1. PubMed ID: 22125874
    [No Abstract]   [Full Text] [Related]  

  • 18. Boceprevir for chronic HCV genotype 1 infection.
    Limaye AR; Draganov PV; Cabrera R
    N Engl J Med; 2011 Jul; 365(2):176; author reply 177-8. PubMed ID: 21751914
    [No Abstract]   [Full Text] [Related]  

  • 19. [New times for the treatment of chronic hepatitis C].
    Gerstoft J; Fomsgaard A
    Ugeskr Laeger; 2012 Mar; 174(12):795. PubMed ID: 22433552
    [No Abstract]   [Full Text] [Related]  

  • 20. [Future of antiviral therapy for chronic hepatitis C. Direct antiviral acting medications].
    Lange CM; Sarrazin C; Zeuzem S
    Pharm Unserer Zeit; 2011 Jan; 40(1):60-7. PubMed ID: 21194084
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.